• linkedin
  • Increase Font
  • Sharebar

    Repeat hydrodistention found safe in treating IC

    Low complication, 30-day readmission rates observed in retrospective review


    No significant changes in capacity

    “We didn’t see any significant changes in bladder capacity over time. We saw a really low complication rate and a really low 30-day readmission rate,” Kirk said. “We also saw only a single patient in our cohort develop new ulceration that wasn’t seen at their initial cystoscopy and hydrodistention.”

    The complication rate with hydrodistention was <1%. The rate of 30-day readmission was 2%. The mean initial anesthetic bladder capacity was 723.9 cc, which was not significantly different from the final capacity of 753.1 cc (p=.15).

    Read: How to reduce opioid use in post-op patients

    Among patients who completed AUA symptom questionnaires before and after hydrodistention, the symptom score improved from 17.1 before treatment to 14.3 post-hydrodistention (p<.001) and the quality of life score improved from 4.3 to 3.6 (p<.001).

    “One of the things we want to do in the future, and what we’re working on, is building this database out to try to understand how we can predict who will benefit from hydrodistention,” Kirk told Urology Times. “We’re working to do multivariable modeling techniques to try to understand what the contributions of various clinical and demographic factors are in terms of being able to predict symptomatic response.”

    More from Urology Times:

    Sacral neuromodulation, botulinum show equal efficacy

    SNS vs. botulinum: Caveats, considerations

    Bother, symptom severity often poorly correlated in LUTS

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available